Drug‐induced liver injury associated with stevens‐Johnson syndrome/toxic epidermal necrolysis: Patient characteristics, causes, and outcome in 36 cases

Harshad Devarbhavi, Sujata Raj, Venu H. Aradya, Vijaykumar T. Rangegowda, Girish P. Veeranna, Rajvir Singh, Vishnuvardan Reddy, Mallikarjun Patil – 5 October 2015 – The liver and skin are the organs most commonly involved in serious adverse drug reactions. Rarely a drug reaction can affect both organs concurrently. The association of drug‐induced liver injury (DILI) and Stevens‐Johnson syndrome (SJS) or toxic epidermal necrosis (TEN) is even rarer and not well studied.

Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation

Ian A. Rowe, Damien C. Tully, Matthew J. Armstrong, Richard Parker, Kathy Guo, Darren Barton, Gene D. Morse, Charles S. Venuto, Colin B. Ogilvie, Ditte L. Hedegaard, Jeffrey F. McKelvy, Flossie Wong‐Staal, Todd M. Allen, Peter Balfe, Jane A. McKeating, David J. Mutimer – 5 October 2015 – Hepatitis C virus (HCV) entry inhibitors have been hypothesized to prevent infection of the liver after transplantation. ITX5061 is a scavenger receptor class B type I antagonist that blocks HCV entry and infection in vitro.

Changes in liver acceptance patterns after implementation of Share 35

Kenneth Washburn, Ann Harper, Timothy Baker, Erick Edwards – 5 October 2015 – The Share 35 policy was implemented June 2013. We sought to evaluate liver offer acceptance patterns of centers under this policy. We compared three 1‐year eras (1, 2, and 3) before and 1 era (4) after the implementation date of the Share 35 policy (June 18, 2013). We evaluated all offers for liver‐only recipients including only those offers for livers that were ultimately transplanted. Logistic regression was used to develop a liver acceptance model.

Subscribe to